GUCY2C Antibody (2543C) [Alexa Fluor™ Plus 594]

• Reactivity: Hu
• Clone: 2543C
• Clonality: Monoclonal
• Host: Rabbit
• Conjugate: Alexa Fluor Plus 594

GUCY2C Antibody (2543C) [Alexa Fluor™ Plus 594] Summary

• Specificity: Detects human Guanylyl Cyclase C/GUCY2C in direct ELISAs.
• Isotype: IgG
• Clonality: Monoclonal
• Host: Rabbit

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for GUCY2C Antibody (2543C) [Alexa Fluor™ Plus 594]

• DIAR6
• EC 4.6.1
• GCC
• GC-C
• guanylate cyclase 2C (heat stable enterotoxin receptor)
• Guanylate Cyclase C
• Guanylyl Cyclase C
• GUC2C
• GUC2CEC 4.6.1.2
• GUCY2C
• heat-stable enterotoxin receptor
• hSTAR
• Intestinal guanylate cyclase
• MUCIL
• STA Receptor
• StAR
• STARSTA receptor

Background

GUCY2C (Guanylyl Cyclase C), also known as heat-stable enterotoxin receptor, is a type I transmembrane protein of the guanylate cyclase (gc) family that signal by producing cGMP (1, 2). GUCY2C contains a 23 amino acid (aa) signal sequence, a 407 aa extracellular region (ECD), a 24 aa transmembrane (TM) segment and a 619 aa cytoplasmic domain (3). The ECD of human GUCY2C shares 71% and 72% aa identity with mouse and rat GUCY2C, respectively (4). GUCY2C was first identified as the intestinal epithelial receptor regulating fluid and electrolyte transport in the secretory diarrhea induced by bacterial enterotoxins (5). Endogenous ligands of GUCY2C include guanylin and uroguanylin (6). GUCY2C in epithelial cells plays an important role in cell dynamics and homeostatic balance of proliferation, metabolism, and differentiation that organizes the guanylyl cyclase C hormone axis (2, 6). GUCY2C is also expressed in the brain and is implicated in attention deficiency and hyperactive behavior (2, 7). CAR-T cell therapy utilizing GUCY2C to treat metastatic colorectal cancer is currently being explored (8).

1. Arshad, N. et al. (2013) J. Biol. Chem. 288:3907.
2. Gibbons, A. V. et al. (2013) Cancer Res. 73:22.
3. de Sauvage, F. J. et al. (1991) J. Biol. Chem. 266:17912.
4. Singh S. et al. (1991) Biochem. Biophys. Res. Comm. 179:1455.
5. Lucas K. et al. (2000) Pharmacol Rev. 52:375.
6. Erik, S. et al. (2016) Mol. Pharmacol. 90:199.
7. Gong, R. et al. (2011) Science. 333:1642.
8. Magee, MS. et al. (2018) Cancer Immuno Res. 6:509.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.